EMEA-001710-PIP02-14-M05

Key facts

Invented name
Zeposia
Active substance
Ozanimod
Therapeutic area
Neurology
Decision number
P/0325/2020
PIP number
EMEA-001710-PIP02-14-M05
Pharmaceutical form(s)
  • Capsule, hard
  • Age-appropriate oral liquid dosage form
Condition(s) / indication(s)
Treatment of multiple sclerosis
Route(s) of administration
Oral use
Contact for public enquiries
Celgene Europe B.V.

Tel. +41 327298500
E-mail: medinfo.emea@celgene.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating
Average
1 rating